Value of post-therapy 177Lu-PSMA images for accurate interpretation of therapy response with 68Ga-PSMA PET/CT

被引:1
|
作者
Tuncel, M. [1 ]
Telli, T. [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Nucl Med, Ankara, Turkey
关键词
Ga-68-PSMA; Lu-177-PSMA; Tumor sink effect; Therapeutic response; PROSTATE-CANCER; GUIDELINES; ANTIGEN;
D O I
10.1016/j.remn.2017.05.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A 54-year-old man with progressive prostate cancer underwent a Ga-68-PSMA PET/CT, which showed lymph node and bone metastases. After 2-cycles of Lu-177-PSMA therapy, the repeated Ga-68-PSMA PET/CT showed decreased radiotracer uptake in lymph node and bones metastases, but there were new lesions which may be compatible with progression or tumour sink-effect. A review of Lu-177-PSMA-therapy images revealed that new lesions in the second PET/CT were the metastatic lesions that progressed after the first PET/CT, and subsequently showed a good response. The patient received additional cycles of Lu-177-PSMA therapy, and the disease regressed further, with a PSA of 0.06 ng/ml. Response evaluation of new therapeutic diagnostics (theranostic) agents needs a review of not only diagnostic PET/CT images, but also post-therapy images and laboratory results. (C) 2017 Elsevier Espana, S.L.U. y SEMNIM. All rights reserved.
引用
收藏
页码:114 / 117
页数:4
相关论文
共 50 条
  • [41] Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
    Groener, Daniel
    Schneider, Sina
    Baumgarten, Justus
    Happel, Christian
    Klimek, Konrad
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (02)
  • [42] 68Ga-PSMA PET/CT in PCa Staging
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 16N - 16N
  • [43] Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival
    Kurth, Jens
    Kretzschmar, Justus
    Aladwan, Hamzeh
    Heuschkel, Martin
    Gummesson, Anja
    Bergner, Carina
    Kundt, Guenther
    Hakenberg, Oliver W.
    Krause, Bernd J.
    Schwarzenboeck, Sarah M.
    NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (11) : 1217 - 1226
  • [44] 68Ga-PSMA PET/CT Protocol Review
    Poel, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S221 - S222
  • [45] Rectal Carcinoma on 68Ga-PSMA PET/CT
    Huang, Yi-Tung Tom
    Fong, William
    Thomas, Paul
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (03) : E167 - E168
  • [46] The Role of Ga-68 PSMA PET / CT in Predicting Lu-177 PSMA Effectiveness: Can We Project the Ga-68 DOTA PET / CT and Lu-177 DOTA Treatment Experience to PSMA?
    Korkmaz, U.
    Soyluoglu, F. S.
    Durmus-Altun, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S468
  • [47] 68Ga-PSMA-11-PET/MRI radiomics in patients receiving 177Lu-617-PSMA-therapy
    Roll, W.
    Schindler, P.
    Masthoff, M.
    Seifert, R.
    Boegemann, M.
    Weckesser, M.
    Rahbar, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S316 - S317
  • [48] Automated synthesis of 68Ga/177Lu-PSMA on the Trasis miniAllinOne
    Sorensen, Mikkel A.
    Andersen, Valdemar L.
    Hendel, Helle Westergren
    Vriamont, Charles
    Warnier, Corentin
    Masset, Julien
    Tri Hien Viet Huynh
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2020, 63 (08): : 393 - 403
  • [49] PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy
    Murthy, Vishnu
    Allen-Auerbach, Martin
    Lam, Richard
    Owen, Dawn
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09) : 1502 - 1503
  • [50] Incidental 68Ga-PSMA Uptake in the Benign Enchondroma-A Rare Finding on 68Ga-PSMA PET/CT
    Singh, Parneet
    Kandula, Keerthana Kiran
    Patel, Ranjan Kumar
    Parida, Girish Kumar
    Agrawal, Kanhaiyalal
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : e525 - e527